With a wide variety of products, included in our urological and gynecological portfolio, urogynecology is already part of Gebro Pharma’s DNA.
The urology and gynecology franchise is one of our strategic pillars and our commitment to urogynecological patients places it as an area of growth in our company.
In 2009 we included Vejicur® in our portfolio, a product indicated in the treatment of non-muscle invasive bladder cancer. This product has played a decisive role in the treatment of many patients since then.
Later, the drugs Ialuril® and Ialuril® Prefill were added. Both are intended to restore the glycosaminoglycan layer of the bladder urothelium. This imbalance is common in situations such as bladder pain syndrome/interstitial cystitis, as well as in recurrent cystitis and radial cystitis or secondary to antitumor agents.
In 2014 we launched Kentera®, the first and unique transdermal oxybutynin. Patients with overactive bladder symptoms found in this patch an innovative product with multiple benefits of comfort, safety and therapeutic adherence.
In 2018 Tebetane® joined our portfolio. This product, owned by Gebro Pharma, is a well-established phytotherapeutic product based on a plant extract from the Pygeum africanum tree, which has a strong anti-inflammatory action on the genitourinary system.
In 2019 Ialuril breaks back into the urogynecological therapeutic arsenal with ialuadapter®, which allows instillation without catheterization, bringing comfort for patients treated with Ialuril® Prefill.
At the beginning of 2021, the drug Tovedeso® (desfesoterodine) was incorporated into our urology and gynecology portfolio. This therapeutic solution, along with Kentera®, completes our portfolio of products for the treatment of the symptoms of overactive bladder syndrome.
